UPDATE: Positive Results Announced from Clinical Trial of BAF-312 (Siponimod) in Secondary Progressi

(Originally released August 25, 2016) Summary

  • Results presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) provided additional details from a 60-month, phase III clinical trial of the experimental oral therapy siponimod (BAF312, Novartis Pharmaceuticals AG) involving 1,651 people with secondary progressive MS.
  • The trial met its primary endpoint of reducing the risk of disability progression compared with inactive placebo. Those on active treatment had a 21% reduced risk of disability progression compared to those on placebo. Secondary endpoints suggested that…

    Favicon of www.nationalmssociety.org da : www.nationalmssociety.org

    Prosegui la lettura...
    Traduci l'articolo...

    Sclerosi Multipla News

    Potrebbe interessarti anche

Argomenti correlati

Pubblicità

Pubblicità